4K Score prostate cancer commercials

Discussion in 'Bio Reference' started by anonymous, Nov 30, 2017 at 10:08 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    are now being seen on prime time. Excellent commercials. These should increase sales of the test.
     

  2. anonymous

    anonymous Guest

    Will probably increase patient foot traffic but it’s more likely that physicians will discourage 4K test since there are cheaper options and lack of reimbursement which is why 4K hasn’t become standard of care as promised.
     
  3. anonymous

    anonymous Guest

    Commercial was on Fox News yesterday
     
  4. anonymous

    anonymous Guest

    ESPN- NBA Primetime - 60 second spot tonight.

    Nice.

    That should help commissions.
     
  5. anonymous

    anonymous Guest

    Wrong audience, too young, not enough income. Needs to be on The Masters.
     
  6. anonymous

    anonymous Guest

    Keep dreaming the test is worthless
     
  7. anonymous

    anonymous Guest

    The commercials have been airing since December. Has there been an impact in the NE? I can only guess the tests have been flying off the shelves.
     
  8. anonymous

    anonymous Guest

    These commercials are powerful and important.
     
  9. anonymous

    anonymous Guest

    Who watches the NBA?
     
  10. anonymous

    anonymous Guest

    WINTERS COLD

    THEB 4K WILL FOLD

    SUMMER'S HOT

    TRANSPORTATION IS NOT

    SPRING HAS A RING

    BILLING IS LESS FILLING

    FALL CAN BE TALL

    SALES WILL>>>>>
     
  11. anonymous

    anonymous Guest

    Rumor on the street is that Miami is pulling 4K from all of BRLI and creating their own group to try and sell it now. PF has clearly lost his interest in BRLI. This devalues BRLI and Quest can now purchase at a bargain basement price that PF can pump said funds into his little 4K entity he’s creating.
     
  12. anonymous

    anonymous Guest

    PF is not losing interest. BRL needs to be saved in order to get the stock price up. He will not devalue it as it will take down the rest of OPKO. He needs to sell it for at least 75% of what he bought it for. You comment is a rumor, which means it is 99% false!
     
  13. anonymous

    anonymous Guest

    That's quite a rumor...if true.

    Loss of 4k does little to the value of the lab, nobody wants it.
     
  14. anonymous

    anonymous Guest

    It’s true. Why do you think they rehired JF and tried to keep it a secret?
     
  15. anonymous

    anonymous Guest

    A new "Men's Health" sales force? What to sell 4K to docs who already already are ordering it? Yea, sure lets spend some more money to sell a 4K test that's already in the toilet!!! Too many reps , too little return!! Wake up!!!! That's why we are in this mess!!

    Too Many Reps!!

    Too Many Managers!!

    Too Many Divisions!!!

    Too Much duplication!!!

    Nice way to demotivate the whole sales force,,,,,,,

    Lets add another another sales force and waste money!! Can someone tell the higher ups this is a disaster before it starts.. Wonder how much Urology business will be lost.
     
  16. anonymous

    anonymous Guest

    The difference in this one is that it’s Miami based. BRLI is NJ. OPK is Miami. That should say enough.
     
  17. anonymous

    anonymous Guest

    A sales force isn’t being added! OPK is pulling 4K back home to Miami. Under 20 folks will be transferred from Bioreference to this shell devision to give the appearance of a sales team dedicated to 4K. This removes 4K from Bioreference and sets this men’s health shell division up as it’s own for a future sell off to a bidder for 4K.

    That leaves Bioreference on its own with no proprietary product and now can be put on the market cheaply as a simple run of the mill lab. The purchaser will simply buy BRLI to gain clients.

    There will be a spin put on it during the earnings call but analysts will see that money was wasted on commercials for 4K that didn’t work and will see this move as OPKO officially leaving Bioreference to fend for itself as a lame duck since it’s past two years earnings have crippled OPKO.

    All being said, this play actually puts Frost back into a positive outlook position from an analysts perspective and stock should increase slightly. Looking further, once sell off of BRLI in Q3 and eventual offload of 4K FY2018/21019 we should see OPKO regaining its strength on future pharmaceutical ventures.

    Buy now, Frosty sure is.
     
  18. anonymous

    anonymous Guest


    Yeah right, what a screaming buy. Both Quest & LC walked after smelling the dung left over from Grodman.
     
  19. anonymous

    anonymous Guest

    So don’t buy. My thoughts are only that, my thoughts. Yes, BRLI is a horrible lab. Shame on Frost for purchasing, good for Grodman to cash out!

    PF wanted a sales entity to push 4K. Fast forward 2 years, it didn’t work.

    He is now pulling back the intellectual property that is 4K to Miami. BRLI is now just a lab.

    Quest walked once they saw 4K was an uphill battle with insurance. They didn’t want the headache nor the expense of trying to prove a champagne level of testing.

    Remove 4K from BRLI and you get a basic lab with, an albeit small, existing customer base. Chump change as it’s said. Their satellite labs are the asset really.

    Quest walked because of the hassle of what can’t be done with 4K. A niche product at best. BRLI’s Genetics division is quickly becoming a commodity as well. Most big hospitals are doing this testing in house now.

    Now, PF can offload this turd and hopefully live out his last 10 years (at best) justifying why people listen and invest in the crap he spews.

    So, don’t buy if you don’t want to. I’m just saying maybe think about it once the obvious hits the fan. Pharmaceutical trials are where you need to focus on with OPKO, PF is done with labs.